Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ursodiol: a cholesterol gallstone solubilizing agent.

C L Rosenbaum1, R J Cluxton

  • 1College of Pharmacy, University of Cincinnati, OH 45267.

Drug Intelligence & Clinical Pharmacy
|December 1, 1988
PubMed
Summary

Ursodiol effectively dissolves cholesterol gallstones by inhibiting hepatic cholesterol synthesis. This bile acid offers a favorable safety profile compared to chenodiol, with fewer adverse reactions like diarrhea.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of school-based health centers on children with asthma.

The Journal of adolescent health : official publication of the Society for Adolescent Medicine·2005
Same author

As-needed dosing of antipsychotic drugs: limitations and guidelines for use in the elderly agitated patient.

The Annals of pharmacotherapy·1993
Same author

Grateful Med: a user-friendly, on-line literature search system.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians·1992
Same author

Inability to justify a part-time clinical pharmacist in a community hospital intensive-care unit.

American journal of hospital pharmacy·1991
Same author

Carboplatin: a new cisplatin analog.

Drug intelligence & clinical pharmacy·1988
Same author

Astemizole: a long-acting, nonsedating antihistamine.

Drug intelligence & clinical pharmacy·1987

Area of Science:

  • Hepatology
  • Gastroenterology
  • Pharmacology

Background:

  • Ursodiol is an FDA-approved bile acid for cholesterol gallstone dissolution.
  • It functions by reducing hepatic cholesterol synthesis and secretion.
  • Ursodiol metabolism results in less accumulation of potentially hepatotoxic lithocholic acid compared to chenodiol.

Purpose of the Study:

  • To evaluate the efficacy and safety of ursodiol in cholesterol gallstone dissolution.
  • To compare ursodiol's adverse reaction profile with that of chenodiol.

Main Methods:

  • The study focuses on the mechanism of action and clinical outcomes of ursodiol.
  • Data on patient response, gallstone dissolution rates, and adverse events are presented.
  • Comparison is made with chenodiol based on reported clinical data.

Main Results:

  • Complete dissolution of cholesterol gallstones achieved in 17% of eligible patients.
  • Recurrence rates exceed 50% in initial responders.
  • Ursodiol exhibits a significantly lower incidence of diarrhea (4%) compared to chenodiol (up to 50%).
  • Elevated aspartate aminotransferase levels observed with chenodiol were not reported with ursodiol.

Conclusions:

  • Ursodiol is an effective treatment for select cholesterol gallstones.
  • Its improved safety profile, particularly reduced gastrointestinal side effects and lack of hepatotoxicity markers, presents a significant advantage over chenodiol.
  • These factors support ursodiol's consideration in hospital formularies for gallstone management.

Related Experiment Videos